IMCC vs. KALA, IBIO, APM, ALTS, PMCB, VBIV, EDSA, UNCY, KPRX, and GHSI
Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include KALA BIO (KALA), iBio (IBIO), Aptorum Group (APM), Janone (ALTS), PharmaCyte Biotech (PMCB), VBI Vaccines (VBIV), Edesa Biotech (EDSA), Unicycive Therapeutics (UNCY), Kiora Pharmaceuticals (KPRX), and Guardion Health Sciences (GHSI). These companies are all part of the "pharmaceutical products" industry.
IM Cannabis (NASDAQ:IMCC) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
KALA BIO has a consensus target price of $16.50, indicating a potential upside of 136.05%. Given KALA BIO's higher possible upside, analysts plainly believe KALA BIO is more favorable than IM Cannabis.
In the previous week, KALA BIO had 12 more articles in the media than IM Cannabis. MarketBeat recorded 14 mentions for KALA BIO and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.44 beat KALA BIO's score of 0.24 indicating that IM Cannabis is being referred to more favorably in the media.
KALA BIO has a net margin of 0.00% compared to IM Cannabis' net margin of -28.03%. IM Cannabis' return on equity of -75.51% beat KALA BIO's return on equity.
7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 13.4% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
KALA BIO received 292 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 66.67% of users gave KALA BIO an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote.
IM Cannabis has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.04, suggesting that its share price is 304% less volatile than the S&P 500.
IM Cannabis has higher revenue and earnings than KALA BIO. IM Cannabis is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.
Summary
KALA BIO beats IM Cannabis on 10 of the 17 factors compared between the two stocks.
Get IM Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IM Cannabis Competitors List
Related Companies and Tools
Free IMCC Stock Alerts